LitAlert ~~

    • Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes.
    • Gensini F, Sestini R, De Luca A, Pinna V, Daniele P, Orzalesi L, Petrella MC, Porfirio B, Papi L.
    • Fam Cancer. 2020 Nov 19. doi: 10.1007/s10689-020-00217-x. Epub ahead of print.
    • Case report
    • I am a PALB2 Previvor.
    • Dinschel A.
    • FORCE. Blog. 2020 Nov 19.
    • Olaparib in BRCA+ Pancreatic Cancer: Cost-effectiveness Analyzed.
    • Nelson R.
    • Medscape. Medical News. 2020 Nov 19.

    Original research:

    Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • MSK Study Suggests Germline Tests May Miss Mosaic Cancer Risk Mutations in Some Patients.
    • GenomeWeb. Technology. 2020 Nov 18.
    • Conference news
    • Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations.
    • Garrett A, Durkie M, Callaway A, Burghel GJ, Robinson R, Drummond J, Torr B, Cubuk C, Berry IR, Wallace AJ, Ellard S, Eccles DM, Tischkowitz M, Hanson H, Turnbull C; CanVIG-UK.
    • J Med Genet. 2020 Nov 18:jmedgenet-2020-107248. doi: 10.1136/jmedgenet-2020-107248. Epub ahead of print.
    • Cancer Previvors in an Active Duty Service Women Population: An Opportunity for Prevention and Increased Force Readiness.
    • Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.
    • Mil Med. 2020 Nov 18:usaa485. doi: 10.1093/milmed/usaa485. Epub ahead of print.
    • Population-Wide Hereditary Breast, Ovarian Cancer Screening in Younger Women is Cost-Effective.
    • [No author given]
    • Clinical OMICs. Molecular Dx. 2020 Nov 17.

    Original research:

    Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.

    • Triple-negative breast cancer: promising prognostic biomarkers currently in development.
    • Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N.
    • Expert Rev Anticancer Ther. 2020 Nov 16. doi: 10.1080/14737140.2021.1840984. Epub ahead of print.
    • Review
    • Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.
    • Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, Kuo F, Chung J, Srivastava RM, Purohit TA, Hoen DR, Mandal R, Setton J, Wu W, Shah R, Qeriqi B, Chang Q, Kendall S, Braunstein L, Weigelt B, Carrillo Albornoz PB, Morris LGT, Mandelker DL, Reis-Filho JS, de Stanchina E, Powell SN, Chan TA, Riaz N.
    • Nat Cancer. 2020 Nov 16:1-9. doi: 10.1038/s43018-020-00139-8. Epub ahead of print.

    Research news: Cancer Patients With BRCA1/2 Mutations Respond Differently to Immunotherapy, Study Shows. (Precision Oncology News; subscription required)

    • Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China.
    • [No author given]
    • Precision Oncology News. 2020 Nov 16.
    • BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives.
    • Molinaro E, Andrikou K, Casadei-Gardini A, Rovesti G.
    • Cancers (Basel). 2020 Nov 12;12(11):E3346. doi: 10.3390/cancers12113346.
    • A review of inherited cancer susceptibility syndromes.
    • Brown GR, Simon M, Wentling C, Spencer DM, Parker AN, Rogers CA.
    • JAAPA. 2020 Nov 6. doi: 10.1097/01.JAA.0000721648.46099.2c. Epub ahead of print.
    • Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.
    • Sanese P, Fasano C, Buscemi G, Bottino C, Corbetta S, Fabini E, Silvestri V, Valentini V, Disciglio V, Forte G, Lepore Signorile M, De Marco K, Bertora S, Grossi V, Guven U, Porta N, Di Maio V, Manoni E, Giannelli G, Bartolini M, Del Rio A, Caretti G, Ottini L, Simone C.
    • iScience. 2020 Oct 7;23(10):101604. doi: 10.1016/j.isci.2020.101604.
    • The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?
    • Matsumoto T, Shiota M.
    • Transl Androl Urol. 2020 Oct;9(5):2289-2291. doi: 10.21037/tau-20-866.

    Original research:

    Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.

    • Genetic testing approaches for hereditary breast cancer: Perspectives from a private diagnostic laboratory.
    • Smith DC, Gardiner SA, Conradie M, Gerber J, Loubser F.
    • S Afr Med J. 2020 Sep 30;110(10):988-992. doi: 10.7196/SAMJ.2020.v110i10.14709.
    • Functional Characterization of PALB2 Variants of Uncertain Significance: Toward Cancer Risk and Therapy Response Prediction.
    • Boonen RACM, Vreeswijk MPG, van Attikum H.
    • Front Mol Biosci. 2020 Sep 16;7:169. doi: 10.3389/fmolb.2020.00169.